MHRA (UK)
OTHER
Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/mL, EL(26)A/46
Published: 11/5/2026Detected: 11/5/2026
Summary preview
Notifies of errors in the dosing table within the SmPC for Co-amoxiclav 250/62.5 mg/5 mL Powder for Oral Suspension, and highlights the need for corrective label/Safety-facing documentation alignment.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
pediatrics
labeling
safety
quality
#MHRA
#SmPC
#dose table error
#co-amoxiclav
#oral suspension
Official Source Document Source Verified
Access the original document directly from MHRA.
More from MHRA (UK)
- Class 3 Medicines Recall: Aspire Pharma Limited, Tropicamide 1% Eye Drops, solution in single dose containers 20 x 0.5ml , EL(26)A/4711/5/2026
- Field Safety Notices: 26 to 30 October 202611/4/2026
- MHRA Safety Roundup: October 202610/30/2026
- Class 2 Medicines Recall: Accord-UK Ltd, Lercanidipine Hydrochloride 10mg Film-Coated Tablets, EL(26)A/4510/29/2026
- Class 2 Medicines Recall: Advanz Pharma Limited, Mynzepli 40 mg/mL solution for injection in pre-filled syringe, EL(26)A/4410/29/2026